Is amantadine (an antiviral and antiparkinsonian medication) effective for treating autism spectrum disorder (ASD) and irritability?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amantadine for Autism Spectrum Disorder and Irritability

Direct Answer

Amantadine is not recommended for treating autism spectrum disorder or irritability, as there is no evidence supporting its use for these conditions, and established guidelines do not include it in treatment algorithms for ASD. 1

Evidence-Based Treatment for Irritability in ASD

The provided evidence contains no data on amantadine for autism or irritability. Current treatment guidelines are clear about what medications are effective:

FDA-Approved First-Line Agents for Irritability

Risperidone (0.5-3.5 mg/day) and aripiprazole (5-15 mg/day) are the only FDA-approved medications for irritability in ASD and should be used as first-line pharmacotherapy when medication is indicated. 1

  • Both medications show significant improvement on the Aberrant Behavior Checklist Irritability subscale compared to placebo 1
  • Risperidone demonstrates efficacy in multiple large RCTs with effects typically starting within 2 weeks 2
  • Aripiprazole has comparable efficacy and safety to risperidone (mean effective dose 5.5 mg/day vs 1.12 mg/day for risperidone) 3

Critical Prescribing Considerations

Medication should only be prescribed after nonpharmacological interventions have been attempted, as risperidone and aripiprazole carry significant metabolic side effects including weight gain, increased prolactin, and metabolic syndrome. 2, 4

  • Combining medication with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbance 1
  • Regular monitoring for metabolic effects is essential but often underemphasized 4
  • Periodic reassessment to determine if ongoing treatment is needed is mandatory 4

Why Amantadine Is Not Appropriate

Amantadine is an antiviral and antiparkinsonian medication with significant CNS side effects including nervousness, anxiety, insomnia, difficulty concentrating, and lightheadedness occurring in approximately 13% of users. 2

  • More serious side effects include marked behavioral changes, delirium, hallucinations, agitation, and seizures, particularly in vulnerable populations 2
  • These adverse effects would be particularly problematic in individuals with ASD who already experience behavioral dysregulation
  • No evidence exists in the literature for amantadine's efficacy in treating core or associated symptoms of ASD 1, 5, 6

Alternative Medication Options When First-Line Agents Fail

If risperidone or aripiprazole are ineffective or not tolerated:

  • For ADHD-type symptoms with impulsivity: Methylphenidate (0.3-0.6 mg/kg/dose, 2-3 times daily) shows efficacy in 49% of children with ASD versus 15.5% on placebo 1, 7
  • For treatment-resistant hyperactivity: Alpha-2 agonists (clonidine or guanfacine) can be considered, though evidence is limited 2, 7
  • Avoid benzodiazepines due to risk of behavioral disinhibition, which can paradoxically worsen irritability 7

References

Guideline

Medication Treatment for Autism Spectrum Disorder (ASD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

An update on pharmacotherapy of autism spectrum disorder in children and adolescents.

International review of psychiatry (Abingdon, England), 2018

Research

Psychopharmacological interventions in autism spectrum disorder.

Expert opinion on pharmacotherapy, 2016

Guideline

Medications for Impulsivity in Autism Spectrum Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.